GENinCode PLC (GENI) — Research Note

Executive summary

GENinCode is a UK-listed clinical-genetics micro-cap selling in-vitro genetic tests for cardiovascular disease prevention (CARDIO inCode, LIPID inCode, THROMBO inCode) and an ovarian cancer surveillance test (ROCA), with commercial operations in Spain (the core revenue engine), a nascent US programme, and NHS/EU pilots. The trajectory across 2020–2025 is one of persistent 15–25% revenue growth on a tiny base (£1.4m→£3.1m) but widening cash losses (£4–6m p.a.), repeated dilutive placings (44p IPO in 2021 → 5p in Jan 2024 → 3.7p in Mar 2025 → 1p in Feb 2026, with shares outstanding rising ~8× to 753m), and a repeatedly delayed FDA De Novo approval for CARDIO inCode-Score 2026-06 Final Results; 2025-09 Interim; 2024-06 Final Results. The single most important valuation issue today is that the equity has an explicit going-concern material uncertainty flag, a cash runway measurable in quarters, and no clear self-funded path to break-even until FDA approval and Thermo Fisher-partnered scale-up actually deliver revenue — the latest FDA target was pushed to end-Q4 2026 2026-06 Final Results.

Fair value estimate

• Methodology: blended sum-of-parts / revenue-multiple against comparable early-commercial diagnostics, cross-checked against post-money cash-plus-optionality. A DCF is not meaningful — the company is loss-making, requires further capital, and the FDA gate is binary.
• Assumptions: FY26 revenue ~£3.5–4.0m (broadly in line with H1-2026 guidance of flat vs. FY25); 2–3× EV/Sales (typical for sub-scale diagnostics with a regulatory catalyst); post-money cash ~£4–5m (after Feb-2026 raise less ~6 months of burn); modest optionality value for CARDIO inCode US launch success and Thermo Fisher pull-through, offset by near-certain future dilution.
• Range: 0.9p – 1.8p per share, implying a fair-value market cap of £7m – £14m (mid ~£10m).
• Current price: 1.05p; current mcap: £7.9m.
• Absolute upside to midpoint: ~+29% (range from ~‑14% to +71%).

The stock is not obviously mispriced. It trades at ~2.5× current-year sales, which is defensible for a growing but sub-scale, cash-burning diagnostic. Upside relies on FDA approval landing and Thermo Fisher delivering material US test volumes; downside is another dilutive placing at a further discount.

Sector context

• Sector classification (Health Care / Health Care) is correct — molecular in-vitro diagnostics.
• Quality/growth/leverage profile is well below typical peers: sub-scale, loss-making, no reimbursement traction in the US yet, high dilution intensity, weak balance sheet.
• Listed AIM/small-cap peers for reference: Yourgene Health, Genedrive, Angle plc — all small-cap molecular diagnostics that have similarly struggled to reach scale profitability. GENI sits in the smallest, most fragile band of this cohort.

Investment thesis (3 bullets)

1. Thermo Fisher collaboration provides genuine distribution leverage — the Dec 2025 non-exclusive 3-year deal to run CARDIO inCode-Score on Thermo's installed QuantStudio 5 Dx base across US/EMEA is a meaningful pull-through channel if the "In-House Assay" phase converts to Medical Device sales post-FDA 2026-06 Final Results.
2. Reimbursement plumbing is largely in place — CARDIO inCode included in 2025 CMS Clinical Lab Fee Schedule (~$500/test) and LIPID inCode already reimbursed at ~$1,229/test average, so revenue can materialise quickly once FDA opens the addressable market 2026-06 Final Results; 2025-01 Placing Circular.
3. ACC/AHA March-2026 guideline update recognising CAD PRS as a "risk enhancer" is a genuine tailwind — for the first time US preventive-cardiology guidelines endorse polygenic risk scoring, which materially validates the product category 2026-06 Final Results.

Key risks (3 bullets)

1. Going-concern material uncertainty is disclosed in the FY25 audit — cash of £0.8m at 31 Dec 2025, post-period £4.7m raised at 1p (a 47% discount), and continued £4–5m annual burn implies another placing is likely within ~12 months; a fourth deeply-dilutive round would compound the ~8× share-count expansion since IPO 2026-06 Final Results going-concern note.
2. FDA De Novo has now slipped multiple times — originally a 510(k) in Aug 2023, converted to De Novo Nov 2023, expected Q2 2025, then Q1 2026, then Q3 2026, now end-Q4 2026 with outstanding deficiencies around ethnic sub-group data and analytical validation 2025-09 Interim; 2026-01 Placing Circular; 2026-06 Final Results. Further slippage would leave the company selling only as an out-of-network LDT.
3. NHS growth stalled — the FY25 statement flags "major strategic, organisational and funding changes across the NHS" as slowing the LIPID inCode rollout, and full-year 2026 revenues to April are only "broadly in line" with prior year 2026-06 Final Results. The single UK anchor customer is now a headwind, not a tailwind.

Operating leverage

On paper GENI has classic diagnostic operating leverage — gross margins are 53–59%, the UK/US lab infrastructure is largely commissioned, and administrative expenses of £6.7m are largely fixed 2026-06 Final Results. In practice, however, the leverage cuts the wrong way at current scale: revenue of £3.1m produces £1.8m gross profit against £6.7m of admin, so contribution from every incremental £1 of revenue is ~59p, and the company needs revenue of roughly £11m before EBITDA breakeven at current cost. A 10–20% revenue beat over current expectations (£350–700k) would still leave a large loss — this is not a stock where an upside surprise drops disproportionately to profit in the near term; the operating-leverage story only becomes real if revenue steps up 3–4× on FDA/Thermo Fisher, at which point the fixed cost base could deliver material EBIT. Until then, the fixed cost base is dilutive to shareholders, not accretive.

Value-trap signals

• Going-concern material uncertainty explicitly disclosed by auditors.
• Repeated deeply-discounted equity raises: 44p (2021) → 5p → 3.7p → 1p, a >97% peak-to-trough dilution price.
• Repeated FDA slippage and repeated guidance walk-downs (H1 2025 trading update cut full-year revenue expectation).
• Insiders participating in placings at ever-lower prices (May 2026 director options struck at 1p) — resetting management economics on new low-water-mark shareholders' backs.
• Recurring dependence on one customer geography (Spain, ~68% of FY25 revenue) with new UK/US channels not yet producing.

Earnings vs. expectations

Disclosure is patchy but a pattern is visible. FY24 guidance issued mid-2024 was met (£2.7m revenue, ~25% growth). H1-2025 trading update (Aug 2025) implicitly maintained expectations, but by 30 Sep 2025 the interim statement cut full-year revenue guidance to £3.3m citing NHS restructuring and FDA delay — a mid-year downgrade 2025-09 Half Year. FY25 actual came in below that at £3.1m 2026-06 Final Results. FDA regulatory milestones have missed repeatedly (originally 2024, then Q2 2025, then Q1 2026, then Q3 2026 submission with approval end-Q4 2026). Pattern: revenue guidance modestly missed, regulatory guidance consistently missed by 12+ months.

Conviction

Conviction: 3 (moderate).

• Supporting: financials are audited and transparent; going-concern disclosure and dilution history remove ambiguity about capital structure fragility; there is a clear near-term binary event (FDA end-Q4 2026) that anchors the valuation range.
• Limiting: fair value is dominated by the FDA outcome, which is genuinely binary and difficult to probability-weight; the true US revenue ramp under Thermo Fisher is impossible to size from disclosure; the "fair" market cap could plausibly be 50% lower or 100% higher depending on which pillar breaks.